• Dendreon Corp., of Seattle, reported a wider-than-expected loss for the first quarter, though revenues of $82 million for sales of prostate cancer vaccine Provenge (sipuleucel-T) fell in line with expecations. The net loss was $103.9 million, or 70 cents per share, compared to analyst estimates of a 63-cents-per-share loss. Dendreon said there was increased demand for Provenge, with 128 new infusion sites added in the first quarter.